Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Retained Earnings: 2011-2025

Historic Retained Earnings for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$721.6 million.

  • Abeona Therapeutics' Retained Earnings rose 10.25% to -$721.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$721.6 million, marking a year-over-year increase of 10.25%. This contributed to the annual value of -$813.3 million for FY2024, which is 8.50% down from last year.
  • Latest data reveals that Abeona Therapeutics reported Retained Earnings of -$721.6 million as of Q3 2025, which was down 0.72% from -$716.5 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Retained Earnings high stood at $688.2 million for Q3 2022, and its period low was -$825.3 million during Q1 2025.
  • In the last 3 years, Abeona Therapeutics' Retained Earnings had a median value of -$749.5 million in 2023 and averaged -$758.5 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first surged by 213.02% in 2022, then crashed by 206.50% in 2023.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Retained Earnings stood at -$655.6 million in 2021, then fell by 6.05% to -$695.3 million in 2022, then declined by 7.79% to -$749.5 million in 2023, then decreased by 8.50% to -$813.3 million in 2024, then increased by 10.25% to -$721.6 million in 2025.
  • Its last three reported values are -$721.6 million in Q3 2025, -$716.5 million for Q2 2025, and -$825.3 million during Q1 2025.